Oral albendazole for the treatment of cutaneous larva migrans
Stephen Jones, Nick J. Reynolds, S. OLIWIECKI, R.R.M. Harman
Abstract
Stephen Jones, Nick J. Reynolds, S. OLIWIECKI, R.R.M. Harman
Abstract
Cutaneous larva migrans is becoming more common in the U.K. with the popularity of tropical countries as holiday destinations. We describe the increasing use of a new benzimidazole derivative, albendazole, which is very effective in the treatment of cutaneous larva migrans. In contrast to thiabendazole, it is virtually free from side-effects and should, we feel, become the treatment of choice for this condition.
OpenAlex reports 60 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Cutaneous larva migrans is becoming more common in the U.K. with the popularity of tropical countries as holiday destinations. We describe the increasing use of a new benzimidazole derivative, albendazole, which is very effective in the treatment of cutaneous larva migrans. In contrast to thiabendazole, it is virtually free from side-effects and should, we feel, become the treatment of choice for this condition.
Key concepts: Albendazole, Cutaneous larva migrans, Larva migrans, Medicine, Dermatology, Helminthiasis, Pathology, Surgery